Isoquinazolinone compound, preparation method and use thereof

By isolate and identifying and preparing the novel quinazolinone alkaloid compounds isoquinazolinone-A and B from tobacco, the problem of insufficient research on secondary metabolites of tobacco endophytes was solved, and the fight against tobacco mosaic virus was achieved. Effective inhibition provides new prospects for pharmacological application.

CN116003416BActive Publication Date: 2024-11-15CHINA TOBACCO YUNNAN IND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211325361.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-27
Publication Date
2024-11-15
Estimated Expiration
2042-10-27

AI Technical Summary

Technical Problem

The prior art studies on secondary metabolites of tobacco endophytes, especially the bioactive compounds of Aspergillus varicose have not been fully developed, and it is difficult to discover new pharmacologically active metabolites.

Method used

A novel quinazolinone alkaloid compounds isoquinazolinone-A and isoquinazolinone-B were isolated and identified by isolate and identified by the fermentation products of endophytic fungi Aspergillus strains, using ethanol ultrasound The compound was prepared and identified by extraction, silica gel column chromatography and high performance liquid chromatography.

Benefits of technology

It has achieved significant inhibitory effect on the fight against tobacco mosaic virus. The compounds are easily obtained, the extraction method is simple, and industrial preparation is feasible. The compound structure is simple and easy to synthesize, providing a new source of anti-tobacco mosaic disease pathological treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116003416B_ABST
    Figure CN116003416B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of plant chemistry, and specifically relates to the preparation of isoquinazolinone A and B and their use in inhibiting tobacco mosaic virus. The isoquinazolinone A and B are isomers, namely 1-(Z) and 2-(E), and the molecular formula is: C 22 H 21 N3O3, which has the following structure: #imgabs0# The present invention also discloses the preparation method and use of the above compound. The isoquinazolinone of the present invention has good anti-tobacco mosaic virus activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of natural product chemistry, and specifically relates to a quinazolinone alkaloid compound in a fermentation product of endophytic Aspergillus versicolor fungus in tobacco, and a preparation method and application thereof. Background Art

[0002] Tobacco is a plant of the genus Nicotiana in the Solanaceae family and is one of the most widely grown cash crops in the world. China is the world's largest tobacco producer and consumer, with an annual output of 400 to 500 million tons. However, there is relatively little research on its endophytes, and the secondary metabolites and biological activities of its endophytes need further study. Therefore, strengthening the comprehensive utilization of secondary metabolites of tobacco endophytes has attracted widespread attention from scientific researchers.

[0003] According to literature reports, more than 4,000 compounds have been identified from tobacco, and the main components include diterpenoids, sesquiterpenoids, flavonoids, alkaloids, coumarins, etc. At the same time, studies have shown that the compounds isolated and identified from endogenous fungi in tobacco have different pharmacological effects, such as antibacterial, antioxidant, anti-tumor, and anti-tobacco mosaic virus. Therefore, strengthening the research on the metabolites of endophytic fungi in tobacco is of great scientific significance for discovering new skeleton-type metabolites with significant activity.

[0004] Aspergillus fungi are widely present in nature. Among them, Aspergillus oryzae is a strain that can produce complex enzymes. In addition to protease, this strain can also produce enzymes with multiple functions such as amylase, saccharifying enzyme, cellulase, phytase, etc., so it is widely used in fermentation industries such as food, feed, and brewing. At the same time, the secondary metabolites of Aspergillus versicolor are also considered to be an important resource to be developed. A series of biologically active natural products have also been isolated from the fermentation products of Aspergillus versicolor from different sources, including alkaloids, peptides, terpenoids and polyphenols.

[0005] The present invention is proposed for this purpose. Summary of the invention

[0006] The invention separates a novel quinazolinone alkaloid compound with anti-tobacco mosaic virus activity from the culture fluid of Aspergillus versicolor strain separated and identified from tobacco, and the compound has not been reported so far.

[0007] Unless otherwise specified, all percentages used in the present invention are by mass.

[0008] The first aspect of the present invention discloses an isoquinazolinone compound, characterized in that it is isomers, 1-(Z) and 2-(E), and the molecular formula is: C 22 H 21 N3O3 has the following structure: Both compounds are brown colloids and are named as isoquinazolinone-A and isoquinazolinone-B, respectively.

[0009] The second aspect of the present invention provides a method for preparing the isoquinazolinone compound described in the first aspect, which specifically comprises the following steps:

[0010] Step 1: Strain isolation and identification:

[0011] Isolation of endophytic fungus Aspergillus versicolor: tobacco rhizomes disinfected with 75% ethanol were placed in a sterile mortar for grinding, and then transferred into a sterile plastic tube after grinding, and centrifuged at 1000-3000 rpm for 2-10 min. 1-100 microliters of supernatant were drawn and spread on a BL plate, and then placed upside down in an incubator and cultured in the dark at 25-30 degrees Celsius for 2-10 days. Single colonies were repeatedly picked for culture and numbered and preserved until a single endophytic fungus colony was obtained, which was confirmed to be Aspergillus versicolor by ITS sequencing (Genbank Accession number MT549144,). The Aspergillus oryzae fungus of the genus Aspergillus is shown in the attached Figure 1 ;

[0012] Step 2: Cultivation of endophytic fungus Aspergillus versicolor:

[0013] The Aspergillus oryzae strain separated in step 1 is inoculated on a potato dextrose agar medium at room temperature, cultured at 25-30° C. for 7-10 days, and then inoculated in a 50-500 ml triangular flask, each triangular flask containing 10-100 ml of potato dextrose medium, and placed at 25-30° C. for shaking culture for 5-10 days to obtain a liquid fermentation strain; the strain is preserved in the General Microbiology Center of China Microbiological Culture Collection Administration, with a preservation number of XΓMXXNo.19910.

[0014] Step 3: Strain amplification and fermentation:

[0015] The liquid fermentation seed obtained by culturing in step 2 is subjected to large-scale fermentation, wherein the large-scale fermentation is carried out in 100 to 1000 100 to 500 mL Fernbach bottles, each bottle containing 50 to 400 g of rice and 50 to 400 mL of distilled water, and each bottle is inoculated with 1.0 to 5.0 mL of the liquid fermentation seed obtained by culturing in step B, and the fermentation product of Aspergillus versicolor is obtained by culturing at 25 to 30° C. for 15 to 45 days;

[0016] Step 4: Extraction of extract:

[0017] The Aspergillus versicolor fermentation product obtained by fermentation in step 3 is ultrasonically extracted with 90wt% to 99wt% ethanol for 2 to 5 times, each time for 30 to 50 minutes, the combined extracts are filtered and concentrated to a small volume, and then ethyl acetate and a 3wt% to 5wt% tartaric acid mixture are added to the concentrate and stirred evenly, and the aqueous phase is separated after standing and stratification, and the pH of the aqueous phase is adjusted to 9.0 with Na2CO3, and extracted again with ethyl acetate, and the ethyl acetate phase is concentrated under reduced pressure to obtain an extract to obtain an alkaloid extraction product for column chromatography separation;

[0018] Step 5: Silica gel column chromatography:

[0019] The extract obtained in step 4 is loaded onto a column using 200-300 mesh silica gel dry method, and subjected to silica gel column chromatography; gradient elution is performed using dichloromethane-methanol solutions with volume ratios of 10:0, 9:1, 8:2, 7:3, 6:4, and 5:5, respectively, and the parts with the same polarity are combined, and the eluents of each part are collected and concentrated; wherein the mass ratio of the silica gel to the extract is 2-5; the eluent obtained when eluted with the dichloromethane-methanol solution with a volume ratio of 9:1 is collected, and is referred to as the first eluent; the first eluent is further separated using a silica gel chromatography column, and gradient eluted using a series of dichloromethane-acetone solutions with volume ratios of 9:1, 8:2, 7:3, 6:4, and 5:5, respectively, and the eluent obtained when eluted with the dichloromethane-acetone solution with a volume ratio of 8:2 is collected, and is referred to as the second eluent.

[0020] Step 6: HPLC separation

[0021] The second eluate finally obtained in step 5 is passed into high performance liquid chromatography for separation and purification. The high performance liquid chromatography separation and purification uses a 21.2 mm × 250 mm, 5 μm Zorbax PrepHT GF chromatographic column, a flow rate of 10 mL / min, a mobile phase of 52 wt% methanol aqueous solution, a DAD detector detection wavelength of 359 nm, 50 μL of the third eluate is injected each time, and the chromatographic peaks after each injection are collected. The chromatographic peaks after each injection are collected, and the eluate corresponding to the retention time of the compound is 25.4 min (i) and 27.8 min (ii), and the solvent is removed under reduced pressure to obtain the isoquinazolinone-A and isoquinazolinone-B.

[0022] The structure of the quinazolinone alkaloid compound prepared by the above method was identified by the following method:

[0023] The compound of the present invention is found to be a brown colloid by appearance observation;

[0024] The UV-visible absorption spectrum showed that it had maximum absorption at 200, 210, 269, and 304 nm, proving the presence of an aromatic ring structure in the compound. High-resolution mass spectrometry (HRESIMS) gave a quasi-molecular ion peak of 376.1662 [M+H] + , the molecular formula of the compound can be determined to be C 22 H 21 N3O3. Combined 1 H and 13 The C and HSQC NMR data are similar to those of protuboxepin K. Compared with protuboxepin K, the C-3 and C-16 of this compound form a double bond. At the same time, the chemical shift of C-7 moves downfield from 127.4 ppm (d) to 154.0 ppm (s), suggesting that C-7 is connected to a hydroxyl group. The above speculation can be obtained by 1 H– 1The HMBC correlation of H3-17 with C-3, C-16, and C-18 in the HCOSY spectrum was confirmed. After the planar structure of the compound was determined, the corresponding configuration was mainly determined by analyzing the ROESY spectrum and ECD spectrum of the compound. In the ROESY spectrum of compound 1, the correlation between NH-2 and H2-18 showed that they had the same orientation, and indirectly proved that the olefin configuration formed by C-3 and C-16 was Z-type. In the ROESY spectrum of compound 2, there was no correlation between NH-2 and H2-18, indicating that the olefin configuration formed by C-3 and C-16 was E-type. The stereo configuration of compound C-14 was obtained by TDDFT ECD calculation. The results showed that the configuration of C-14 was 14R. So far, the structure of the compound of the present invention has been confirmed. Compounds 1 and 2 were named: isoquinazolinone-A and isoquinazolinone-B, respectively.

[0025] Table 1 Compounds 1 and 2 1 H NMR and 13 C NMR data (CD3OD)

[0026]

[0027] The beneficial effects of the present invention are as follows:

[0028] 1. The isoquinazolinone compound of the present invention is separated from the fermentation product of the endophytic Aspergillus versicolor fungus strain in tobacco. Since endophytic fungi are easy to achieve batch fermentation production, the raw materials of the compound of the present invention are easy to obtain; the extraction method of the compound is simple, it is easy to separate and obtain, and industrial preparation is easy to achieve.

[0029] 2. The isoquinazolinone compound of the present invention is a new quinazolinone alkaloid compound isolated from the fermentation product of Aspergillus versicolor fungus endogenous to tobacco. In the experiment against tobacco mosaic virus, the relative inhibition rates of compounds 1 and 2 were 33.6±2.4% and 26.7±2.4%, respectively, which were close to the relative inhibition rate of the reference substance Ningnanmycin (33.2±2.2%). The quinazolinone compound of the present invention has a good application prospect in the preparation of anti-tobacco mosaic virus drugs.

[0030] 3. The molecular structure of the compound of the present invention is also simple and easy to realize artificial synthesis, and the subsequent industrialization can also be realized through artificial synthesis.

[0031] 4. The preparation method of the present invention adopts a preparation method combining acid-base controlled extraction of isoquinazolinone-A and quinazolinone-B, conventional column chromatography and high performance liquid chromatography. The compound preparation operation process is simple, the obtained compound of the present invention has high purity, and the quality and purity of the compound in subsequent industrial production are guaranteed.

[0032] 5. The quinazolinone compound of the present invention is safe and non-toxic, exhibits good anti-tobacco mosaic virus activity, and can provide an ideal new skeleton type drug source molecule for the prevention and treatment of tobacco mosaic disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 Schematic diagram of Aspergillus versicolor; a, colony morphology; b, microscopic morphology.

[0034] Figure 2 is the carbon nuclear magnetic resonance spectrum of the compound isoquinazolinone-A.

[0035] Figure 3 is the hydrogen nuclear magnetic resonance spectrum of the compound isoquinazolinone-A.

[0036] Figure 4 The main HMBC and 1H-1HCOSY correlations for the compound isoquinazolinone-A.

[0037] Figure 5 It is the ECD diagram of the compound isoquinazolinone-A.

[0038] Figure 6 is the carbon nuclear magnetic resonance spectrum of the compound isoquinazolinone-B.

[0039] Figure 7 is the hydrogen nuclear magnetic resonance spectrum of the compound isoquinazolinone-B.

[0040] Figure 8 The main HMBC and 1H-1HCOSY correlations for the compound isoquinazolinone-B. DETAILED DESCRIPTION

[0041] The present invention is further described below by way of examples, but is not limited to the examples. The experimental methods without specific conditions in the examples are usually carried out according to conventional conditions and conditions described in the manual, or according to the conditions recommended by the manufacturer. The general equipment, materials, reagents, etc. used can be obtained from commercial sources unless otherwise specified. The raw materials required in the following examples are all commercially available.

[0042] The raw materials used in the present invention are not affected by the type of culture medium. The present invention is further described below using the culture medium of the Aspergillus versicolor strain isolated and identified from tobacco in Yunnan:

[0043] Example 1

[0044] The liquid fermentation seeds obtained by culture were fermented on a large scale in 500 500mL Fernbach bottles, each bottle containing 180g of rice and 180mL of distilled water, and 2.5mL of the liquid fermentation seeds obtained by culture were inoculated in each bottle, and cultured at 25-30°C for 30 days to obtain the Aspergillus versicolor fermentation product. The fermentation product was ultrasonically extracted 3 times with 95% ethanol, each extraction for 30 minutes; the extracts were combined and added to a mixed solution of ethyl acetate and 3% tartaric acid (ethyl acetate: tartaric acid = 97:3, mass ratio) and stirred thoroughly, and the mixed solution was allowed to stand for stratification to separate the aqueous phase, and the aqueous phase was adjusted to a pH value of 9.0 with a Na2CO3 solution, and extracted again with ethyl acetate; the separated ethyl acetate phase was concentrated under reduced pressure to an extract, and 580g of the extract was obtained. The extract was mixed with 1.0 kg of 80-120 mesh silica gel, loaded with 3.0 kg of 200 mesh silica gel for silica gel column chromatography, and gradient eluted with dichloromethane-methanol in a volume ratio of 20:1, 8:2, 7:3, 6:4, 5:5. The same parts were combined under TLC monitoring to obtain 5 parts, wherein the dichloromethane-methanol elution part in a volume ratio of 7:3 was concentrated, eluted again with dichloromethane-acetone solution in a volume ratio of 9:1, 8:2, 7:3, 6:4, 1:1, and then separated by Agilent 1100 preparative high performance liquid chromatography, with 59% methanol as the mobile phase, and Zorbax PrepHT A GF column (21.2×250 mm, 5 μm) was used as the stationary phase. The flow rate was 20 mL / min. The detection wavelength of the DAD detector was 359 nm. 50 μL was injected each time. The eluents corresponding to the chromatographic peaks at retention times of 25.4 min and 27.8 min were collected respectively. The solvent was removed under reduced pressure to obtain the new compound pure products 1 and 2.

[0045] Example 2

[0046] The liquid fermentation seeds obtained by culture were fermented on a large scale in 250 1.0L Fernbach bottles, each bottle containing 360g of rice and 360mL of distilled water, and 5.0mL of the liquid fermentation seeds obtained by culture were inoculated in each bottle, and cultured at 25-30°C for 30 days to obtain the Aspergillus versicolor fermentation product. The fermentation product was ultrasonically extracted 3 times with 95% ethanol, each extraction for 30 minutes; the extracts were combined and added to a mixed solution of ethyl acetate and 3% tartaric acid (ethyl acetate: tartaric acid = 97:3, mass ratio) and stirred thoroughly, and the mixed solution was allowed to stand for stratification to separate the aqueous phase, and the aqueous phase was adjusted to a pH value of 9.0 with a Na2CO3 solution, and extracted again with ethyl acetate; the separated ethyl acetate phase was concentrated under reduced pressure to obtain an extract, and 610g of the extract was obtained. The extract was mixed with 1.0 kg of 80-120 mesh silica gel, and 3.2 kg of 200 mesh silica gel was loaded into a column for silica gel column chromatography. The extract was gradient eluted with dichloromethane-methanol in a volume ratio of 20:1, 8:2, 7:3, 6:4, and 5:5. The same parts were combined under TLC monitoring to obtain 5 parts, among which the dichloromethane-methanol elution part in a volume ratio of 8:2 was concentrated, and the dichloromethane-acetone solution in a volume ratio of 9:1, 8:2, 7:3, 6:4, and 1:1 was used for elution again, and then separated by Agilent 1100 preparative high performance liquid chromatography, with 59% methanol as the mobile phase, and Zorbax PrepHT A GF column (21.2×250 mm, 5 μm) was used as the stationary phase. The flow rate was 20 mL / min. The detection wavelength of the DAD detector was 359 nm. 50 μL was injected each time. The eluate corresponding to the retention time of compound 1 was collected at 25.4 min. The fractions were combined and the solvent was removed under reduced pressure to obtain the pure product of the new compound.

[0047] Example 3

[0048] The structure of the quinazolinone alkaloid compound prepared by the above method was identified by the following method:

[0049] Appearance observation revealed that the compound of the present invention was a brown colloid.

[0050] The UV-visible absorption spectrum showed that it had maximum absorption at 200, 210, 269, and 304 nm, proving the presence of an aromatic ring structure in the compound. High-resolution mass spectrometry (HRESIMS) gave a quasi-molecular ion peak of 376.1662 [M+H] + , the molecular formula of the compound can be determined to be C 22 H 21 N3O3. Combined 1 H and 13The C and HSQC NMR data are similar to those of protuboxepin K. Compared with protuboxepin K, the C-3 and C-16 of this compound form a double bond. At the same time, the chemical shift of C-7 moves downfield from 127.4 ppm (d) to 154.0 ppm (s), suggesting that C-7 is connected to a hydroxyl group. The above speculation can be obtained by 1 H– 1 The HMBC correlation of H3-17 with C-3, C-16, and C-18 in the HCOSY spectrum was confirmed. After the planar structure of the compound was determined, the corresponding configuration was mainly determined by analyzing the ROESY spectrum and ECD spectrum of the compound. In the ROESY spectrum of compound 1, the correlation between NH-2 and H2-18 showed that they had the same orientation, and indirectly proved that the olefin configuration formed by C-3 and C-16 was Z-type. In the ROESY spectrum of compound 2, there was no correlation between NH-2 and H2-18, indicating that the olefin configuration formed by C-3 and C-16 was E-type. The stereo configuration of compound C-14 was obtained by TDDFT ECD calculation. The results showed that the configuration of C-14 was 14R. So far, the structure of the compound of the present invention has been confirmed. Compounds 1 and 2 are named: Isoquinazolinone-A and B, respectively.

[0051] Example 4

[0052] Any compound prepared in Examples 1 to 3 was tested for anti-tobacco mosaic virus activity, and the test results are as follows:

[0053] The half-leaf method was used to determine the anti-tobacco mosaic virus activity of the compounds of the present invention when the mass concentration of the agents was 20 μM. From 5 to 6 flue-cured tobacco plants, leaves suitable for testing (normal leaves, free of disease and insects) were selected, and the leaves were evenly sprinkled with fine corundum. The reserved tobacco mosaic virus source (3.0×10 -3 ) is evenly spread on the leaves sprinkled with corundum. After all the selected leaves are infected, they are immediately placed in a culture dish filled with liquid medicine for 20 minutes. Take them out, sprinkle the water droplets and liquid on the leaves, and restore the two halves of the leaves and place them on an enamel glass covered with toilet paper for moisture retention. The temperature is controlled at (23±2)℃ and placed in a greenhouse under natural light. Dead spots can be seen in 2 to 3 days. For each treatment, the other half of the leaf is set as a control, and another group of treatments with commercial ningnanmycin is set as a comparison. The relative inhibition rate is calculated according to the formula.

[0054] XI%=(CK-T) / CK×100%

[0055] X: relative inhibition rate (%), CK: number of necrotic spots on half of the infected leaf immersed in clean water, T: number of necrotic spots on half of the infected leaf immersed in drug solution.

[0056] The relative inhibition rate of the compound is 33.6±2.4%, which is close to the relative inhibition rate of the reference substance Ningnanmycin (33.2±2.2%), indicating that the compound has good anti-tobacco mosaic virus activity.

[0057] The above description is only used to introduce the specific implementation methods of the present invention in detail, but the technical solution proposed by the present invention is not limited to the above method. Without departing from the basic principles of the present technology, equivalent modifications and changes made by those skilled in the art to the technology proposed by the present invention should be included in the scope of the claims of the present invention.

Claims

1. An isoquinazolinone compound, characterized in that It has isomers, 1-(Z) and 2-(E), with the molecular formula: C 22 H 21 N3O3 has the following structure: .

2. The method for preparing a quinazolinone compound according to claim 1, wherein: The following steps are involved: (1) Extraction: The Aspergillus versicolor strain YATS1111 was subjected to solid fermentation, and the fermentation product was ultrasonically extracted with 90wt%~99wt% ethanol and filtered and concentrated. Then, a mixed solution of ethyl acetate and tartaric acid was added and stirred evenly. After standing and stratification, the aqueous phase was separated. The pH value of the aqueous phase was adjusted with Na2CO3, and ethyl acetate was used for extraction again. The ethyl acetate phase was concentrated under reduced pressure to obtain an extract. (2) Silica gel column chromatography: The extract obtained in step (1) is subjected to silica gel column chromatography by dry-packing with 200-300 mesh silica gel; gradient elution is performed with dichloromethane-methanol solutions having volume ratios of 10:0, 9:1, 8:2, 7:3, 6:4, and 5:5, respectively; the fractions of the same polarity are combined, and the eluents of each fraction are collected and concentrated; wherein the mass ratio of the silica gel to the extract is 1:(2-5); the eluent obtained when eluted with dichloromethane-methanol solution having a volume ratio of 9:1 is collected, and is referred to as the first eluent; the eluent is further separated by silica gel chromatography column, and gradient eluted with dichloromethane-acetone solutions having volume ratios of 9:1, 8:2, 7:3, 6:4, and 5:5, respectively; the eluent obtained when eluted with dichloromethane-acetone solution having a volume ratio of 8:2 is collected, and is referred to as the second eluent; (3) High performance liquid chromatography separation: The second eluate obtained in step (2) is passed through a high performance liquid chromatography for separation and purification; the high performance liquid chromatography separation and purification adopts a 21.2 mm × 250 mm, 5 μ The flow rate was 10 mL / min, and the mobile phase was 52 wt% methanol-water solution; the DAD detector detection wavelength was 359 nm, and the third eluent was injected 50 μ L; collecting the eluate corresponding to the retention time of the chromatographic peak compound at 25.4 min and 27.8 min after each injection, and removing the solvent under reduced pressure to obtain the pure alkaloid compound.

3. The preparation method according to claim 2, characterized in that: In step (1), a mixture of ethyl acetate and 3 wt% to 5 wt% tartaric acid is used, and the pH value of the aqueous phase is adjusted to 9.0 using Na2CO3.

4. Use of the isoquinazolinone compound according to claim 1 in the preparation of an anti-tobacco mosaic virus drug.